PDF herunterladen
J Reconstr Microsurg 2018; 34(08): 642-650
DOI: 10.1055/s-0038-1661336
Original Article: WSRM 2017 Scientific Paper
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Cell-Based Therapies in Vascularized Composite Allotransplantation

Krishna S. Vyas
1   Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota
,
Anita T. Mohan
1   Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota
,
Shane D. Morrison
2   Division of Plastic Surgery, Department of Surgery, University of Washington, Seattle, Washington
,
Duy C. Tran
3   Stanford University School of Medicine, Stanford, California
,
Samir Mardini
1   Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota
› Institutsangaben Funding and Financial Disclosures The authors have no financial disclosures to declare and there was no funding obtained for the production of this article.
Weitere Informationen

Publikationsverlauf

27. November 2017

28. April 2018

Publikationsdatum:
26. Juni 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background Dendritic cells (DCs) are bone marrow-derived, professional antigen-presenting cells with tolerogenic function. The ability of DCs to regulate alloantigen-specific T cell responses and to promote tolerance has aligned them ideally for a role in vascularized composite allotransplantation (VCA). In this study, we summarize the current evidence for DC therapies for tolerance induction to alleviate the requirement for chronic immunosuppression.

Method A comprehensive and structured review of manuscripts published on VCA was performed using the MEDLINE and PubMed databases. All eligible studies published from the year 2000 to 2017 were included in the final results.

Result Nineteen original preclinical and clinical studies that employed cell therapy for VCA were included in this review. In vivo DC therapy was found to direct the alloimmune response toward either transplant rejection or tolerance in VCA models. While injection of mature DCs rapidly increases T-cell activity in humans and promotes transplant rejection, the injection of immature DCs acts as an immunosuppressant and inhibits T-cell activity. In addition to immature DCs, mesenchymal stem cells were also found to have a positive effect on allotransplantation of solid organs and bone marrow via cytokine expression which decreases the alloreactive effector lymphocytes and increases CD4+/CD25+/FoxP3 Tregs. Despite the promising findings, the efficacy of cell-based therapies varies greatly across studies, partly due to different methods of cell isolation and purification techniques, source, route and timing of administration, and combination immunosuppressive therapy.

Conclusion Additional research is needed to evaluate the efficacy and safety of DC and other cell-based therapeutic measures in human allotransplant recipients. Future direction will focus on the development of novel methods to reduce immunosuppression and develop more individualized management, as well as the clinical application of basic research in the mechanisms of immunologic tolerance.

Keywords

tolerogenic dendritic cells - dendritic cells - composite tissue allotransplantation - vascularized composite allotransplantation - immunosuppressive - cell-based therapy - immune tolerance - transplantation - immature DCs - DCs

Supplementary Material

 

  • References

  • 1 Petit F, Minns AB, Dubernard JM, Hettiaratchy S, Lee WP. Composite tissue allotransplantation and reconstructive surgery: first clinical applications. Ann Surg 2003; 237 (01) 19-25
    CrossrefPubMedGoogle Scholar
  • 2 Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation--how much of the promise has been realized?. Nat Med 2005; 11 (06) 605-613
    CrossrefPubMedGoogle Scholar
  • 3 Swearingen B, Ravindra K, Xu H, Wu S, Breidenbach WC, Ildstad ST. Science of composite tissue allotransplantation. Transplantation 2008; 86 (05) 627-635
    CrossrefPubMedGoogle Scholar
  • 4 Solari MG, Srinivasan S, Boumaza I. , et al. Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun 2009; 32 (02) 116-124
    CrossrefPubMedGoogle Scholar
  • 5 Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137 (05) 1142-1162
    CrossrefPubMedGoogle Scholar
  • 6 Legge KL, Gregg RK, Maldonado-Lopez R. , et al. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J Exp Med 2002; 196 (02) 217-227
    CrossrefPubMedGoogle Scholar
  • 7 Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007; 7 (01) 19-30
    CrossrefPubMedGoogle Scholar
  • 8 Jung YJ, Ju SY, Yoo ES. , et al. MSC-DC interactions: MSC inhibit maturation and migration of BM-derived DC. Cytotherapy 2007; 9 (05) 451-458
    CrossrefPubMedGoogle Scholar
  • 9 Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7 (08) 610-621
    CrossrefPubMedGoogle Scholar
  • 10 Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol 2007; 82 (06) 1365-1374
    CrossrefPubMedGoogle Scholar
  • 11 Thomson AW, Sacks JM, Kuo YR. , et al. Dendritic cell therapy in composite tissue allotransplantation. Transplant Proc 2009; 41 (02) 537-538
    CrossrefPubMedGoogle Scholar
  • 12 Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation--friend or foe?. Immunity 2001; 14 (04) 357-368
    CrossrefPubMedGoogle Scholar
  • 13 Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation. Semin Immunol 2011; 23 (04) 252-263
    CrossrefPubMedGoogle Scholar
  • 14 Leishman AJ, Silk KM, Fairchild PJ. Pharmacological manipulation of dendritic cells in the pursuit of transplantation tolerance. Curr Opin Organ Transplant 2011; 16 (04) 372-378
    CrossrefPubMedGoogle Scholar
  • 15 van Kooten C, Lombardi G, Gelderman KA. , et al. Dendritic cells as a tool to induce transplantation tolerance: obstacles and opportunities. Transplantation 2011; 91 (01) 2-7
    CrossrefPubMedGoogle Scholar
  • 16 Lu L, Li W, Fu F. , et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 1997; 64 (12) 1808-1815
    CrossrefPubMedGoogle Scholar
  • 17 Thomson AW, Lu L, Subbotin VM. , et al. In vitro propagation and homing of liver-derived dendritic cell progenitors to lymphoid tissues of allogeneic recipients. Implications for the establishment and maintenance of donor cell chimerism following liver transplantation. Transplantation 1995; 59 (04) 544-551
    CrossrefPubMedGoogle Scholar
  • 18 Terness P, Kleist C, Simon H. , et al. Mitomycin C-treated antigen-presenting cells as a tool for control of allograft rejection and autoimmunity: from bench to bedside. Hum Immunol 2009; 70 (07) 506-512
    CrossrefPubMedGoogle Scholar
  • 19 Oluwole OO, Depaz HA, Gopinathan R. , et al. Indirect allorecognition in acquired thymic tolerance: induction of donor-specific permanent acceptance of rat islets by adoptive transfer of allopeptide-pulsed host myeloid and thymic dendritic cells. Diabetes 2001; 50 (07) 1546-1552
    CrossrefPubMedGoogle Scholar
  • 20 Mirenda V, Berton I, Read J. , et al. Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004; 15 (04) 987-997
    CrossrefPubMedGoogle Scholar
  • 21 Sacks JM, Kuo YR, Taieb A. , et al. Prolongation of composite tissue allograft survival by immature recipient dendritic cells pulsed with donor antigen and transient low-dose immunosuppression. Plast Reconstr Surg 2008; 121 (01) 37-49
    CrossrefPubMedGoogle Scholar
  • 22 Kuo YR, Huang CW, Goto S. , et al. Alloantigen-pulsed host dendritic cells induce T-cell regulation and prolong allograft survival in a rat model of hindlimb allotransplantation. J Surg Res 2009; 153 (02) 317-325
    CrossrefPubMedGoogle Scholar
  • 23 Ikeguchi R, Sacks JM, Unadkat JV. , et al. Long-term survival of limb allografts induced by pharmacologically conditioned, donor alloantigen-pulsed dendritic cells without maintenance immunosuppression. Transplantation 2008; 85 (02) 237-246
    CrossrefPubMedGoogle Scholar
  • 24 Horibe EK, Sacks J, Unadkat J. , et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol 2008; 18 (04) 307-318
    CrossrefPubMedGoogle Scholar
  • 25 Eun SC, Baek RM, Park CG. Prolongation of the rat composite tissue allograft survival by the combination of tolerogenic immature dendritic cells and short-term treatment with FK506. Transplant Proc 2013; 45 (05) 1792-1796
    CrossrefPubMedGoogle Scholar
  • 26 Liu F, Luo X, Lan S. , et al. Immunosuppression with a combination of triptolide and cyclosporin A in rat vascularized groin flap allotransplantation. Plast Reconstr Surg 2013; 131 (03) 343e-350e
    CrossrefPubMedGoogle Scholar
  • 27 Wang Y, Zheng Z, Zhu X. , et al. The amelioration of composite tissue allograft rejection by TIM-3-modified dendritic cell: regulation of the balance of regulatory and effector T cells. Immunol Lett 2016; 169: 15-22
    CrossrefPubMedGoogle Scholar
  • 28 Yamano T, Watanabe S, Hasegawa H. , et al. Ex vivo-expanded DCs induce donor-specific central and peripheral tolerance and prolong the acceptance of donor skin grafts. Blood 2011; 117 (09) 2640-2648
    CrossrefPubMedGoogle Scholar
  • 29 Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178 (11) 7018-7031
    CrossrefPubMedGoogle Scholar
  • 30 Fischer RT, Turnquist HR, Wang Z, Beer-Stolz D, Thomson AW. Rapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen-specific CD8(+) T cells in vitro and in vivo. Transpl Immunol 2011; 25 (01) 20-26
    CrossrefPubMedGoogle Scholar
  • 31 Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: microchimerism and allograft survival. Immunol Today 1996; 17 (12) 577-584 , discussion 588
    CrossrefPubMedGoogle Scholar
  • 32 Kuo YR, Chen CC, Goto S, Lin PY, Wei FC, Chen CL. Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation. Clin Dev Immunol 2012; 2012 (12) 854846
    PubMedGoogle Scholar
  • 33 Djouad F, Charbonnier LM, Bouffi C. , et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25 (08) 2025-2032
    CrossrefPubMedGoogle Scholar
  • 34 English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 2008; 115 (01) 50-58
    CrossrefPubMedGoogle Scholar
  • 35 Li M, Sun K, Welniak LA, Murphy WJ. Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease. Expert Opin Pharmacother 2008; 9 (13) 2305-2316
    CrossrefPubMedGoogle Scholar
  • 36 Zhang X, Jiao C, Zhao S. Role of mesenchymal stem cells in immunological rejection of organ transplantation. Stem Cell Rev 2009; 5 (04) 402-409
    CrossrefPubMedGoogle Scholar
  • 37 English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 2013; 91 (01) 19-26
    CrossrefPubMedGoogle Scholar
  • 38 Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 2011; 6: 457-478
    CrossrefPubMedGoogle Scholar
  • 39 Bartholomew A, Sturgeon C, Siatskas M. , et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30 (01) 42-48
    CrossrefPubMedGoogle Scholar
  • 40 Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med 2013; 2 (06) 455-463
    CrossrefPubMedGoogle Scholar
  • 41 Cui L, Yin S, Liu W, Li N, Zhang W, Cao Y. Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng 2007; 13 (06) 1185-1195
    CrossrefPubMedGoogle Scholar
  • 42 Fang B, Song Y, Lin Q. , et al. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant 2007; 11 (07) 814-817
    CrossrefPubMedGoogle Scholar
  • 43 Wan CD, Cheng R, Wang HB, Liu T. Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model. Hepatobiliary Pancreat Dis Int 2008; 7 (01) 29-33
    PubMedGoogle Scholar
  • 44 Constantin G, Marconi S, Rossi B. , et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009; 27 (10) 2624-2635
    CrossrefPubMedGoogle Scholar
  • 45 González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009; 60 (04) 1006-1019
    CrossrefPubMedGoogle Scholar
  • 46 Gonzalez-Rey E, Anderson P, González MA, Rico L, Büscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009; 58 (07) 929-939
    CrossrefPubMedGoogle Scholar
  • 47 Crop MJ, Baan CC, Korevaar SS. , et al. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol 2010; 162 (03) 474-486
    CrossrefPubMedGoogle Scholar
  • 48 Gonzalez-Rey E, Gonzalez MA, Varela N. , et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 2010; 69 (01) 241-248
    CrossrefPubMedGoogle Scholar
  • 49 Engela AU, Baan CC, Dor FJ, Weimar W, Hoogduijn MJ. On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol 2012; 3: 126
    PubMedGoogle Scholar
  • 50 Izadpanah R, Trygg C, Patel B. , et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem 2006; 99 (05) 1285-1297
    CrossrefPubMedGoogle Scholar
  • 51 Liu TM, Martina M, Hutmacher DW, Hui JH, Lee EH, Lim B. Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells 2007; 25 (03) 750-760
    CrossrefPubMedGoogle Scholar
  • 52 Noël D, Caton D, Roche S. , et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res 2008; 314 (07) 1575-1584
    CrossrefPubMedGoogle Scholar
  • 53 Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci 2012; 1266: 107-117
    CrossrefPubMedGoogle Scholar
  • 54 De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A. , et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12 (05) 574-591
    CrossrefPubMedGoogle Scholar
  • 55 Figueroa FE, Carrión F, Villanueva S, Khoury M. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res 2012; 45 (03) 269-277
    PubMedGoogle Scholar
  • 56 Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 2010; 21 (12) 1641-1655
    CrossrefPubMedGoogle Scholar
  • 57 Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 2008; 36 (06) 733-741
    CrossrefPubMedGoogle Scholar
  • 58 Casiraghi F, Azzollini N, Todeschini M. , et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012; 12 (09) 2373-2383
    CrossrefPubMedGoogle Scholar
  • 59 Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Weimar W, Hoogduijn MJ. Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev 2010; 19 (12) 1843-1853
    CrossrefPubMedGoogle Scholar
  • 60 de Girolamo L, Lucarelli E, Alessandri G. , et al; Italian Mesenchymal Stem Cell Group. Mesenchymal stem/stromal cells: a new “cells as drugs” paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des 2013; 19 (13) 2459-2473
    CrossrefPubMedGoogle Scholar
  • 61 Di Ianni M, Del Papa B, De Ioanni M. , et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008; 36 (03) 309-318
    CrossrefPubMedGoogle Scholar
  • 62 Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2 (04) 34
    CrossrefPubMedGoogle Scholar
  • 63 Hong ZF, Huang XJ, Yin ZY, Zhao WX, Wang XM. Immunosuppressive function of bone marrow mesenchymal stem cells on acute rejection of liver allografts in rats. Transplant Proc 2009; 41 (01) 403-409
    CrossrefPubMedGoogle Scholar
  • 64 Inoue S, Popp FC, Koehl GE. , et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006; 81 (11) 1589-1595
    CrossrefPubMedGoogle Scholar
  • 65 Itakura S, Asari S, Rawson J. , et al. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant 2007; 7 (02) 336-346
    CrossrefPubMedGoogle Scholar
  • 66 Kuo YR, Chen CC, Goto S. , et al. Modulation of immune response and T-cell regulation by donor adipose-derived stem cells in a rodent hind-limb allotransplant model. Plast Reconstr Surg 2011; 128 (06) 661e-672e
    CrossrefPubMedGoogle Scholar
  • 67 Kuo YR, Goto S, Shih HS. , et al. Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation 2009; 87 (12) 1769-1777
    CrossrefPubMedGoogle Scholar
  • 68 Lawitschka A, Ball L, Peters C. Nonpharmacologic treatment of chronic graft-versus-host disease in children and adolescents. Biol Blood Marrow Transplant 2012; 18 (1, Suppl): S74-S81
    CrossrefPubMedGoogle Scholar
  • 69 Le Blanc K, Frassoni F, Ball L. , et al; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371 (9624): 1579-1586
    CrossrefPubMedGoogle Scholar
  • 70 Pan H, Zhao K, Wang L. , et al. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation. J Surg Res 2010; 160 (02) 315-324
    CrossrefPubMedGoogle Scholar
  • 71 Tan J, Wu W, Xu X. , et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307 (11) 1169-1177
    CrossrefPubMedGoogle Scholar
  • 72 Wu GD, Nolta JA, Jin YS. , et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 2003; 75 (05) 679-685
    CrossrefPubMedGoogle Scholar
  • 73 Zhou HP, Yi DH, Yu SQ. , et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 2006; 38 (09) 3046-3051
    CrossrefPubMedGoogle Scholar
  • 74 Plock JA, Schnider JT, Solari MG, Zheng XX, Gorantla VS. Perspectives on the use of mesenchymal stem cells in vascularized composite allotransplantation. Front Immunol 2013; 4: 175
    PubMedGoogle Scholar
  • 75 Kuo YR, Chen CC, Shih HS. , et al. Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with T-cell regulation in a swine hind-limb model. Plast Reconstr Surg 2011; 127 (02) 569-579
    CrossrefPubMedGoogle Scholar
  • 76 Kuo YR, Chen CC, Goto S, Huang YT, Tsai CC, Yang MY. Proteomic analysis in serum of rat hind-limb allograft tolerance induced by immunosuppressive therapy with adipose-derived stem cells. Plast Reconstr Surg 2014; 134 (06) 1213-1223
    CrossrefPubMedGoogle Scholar
  • 77 Jeong SH, Ji YH, Yoon ES. Immunosuppressive activity of adipose tissue-derived mesenchymal stem cells in a rat model of hind limb allotransplantation. Transplant Proc 2014; 46 (05) 1606-1614
    CrossrefPubMedGoogle Scholar
  • 78 Cheng HY, Ghetu N, Huang WC. , et al. Syngeneic adipose-derived stem cells with short-term immunosuppression induce vascularized composite allotransplantation tolerance in rats. Cytotherapy 2014; 16 (03) 369-380
    CrossrefPubMedGoogle Scholar
  • 79 Plock JA, Schnider JT, Schweizer R. , et al. The influence of timing and frequency of adipose-derived mesenchymal stem cell therapy on immunomodulation outcomes after vascularized composite allotransplantation. Transplantation 2017; 101 (01) e1-e11
    CrossrefPubMedGoogle Scholar
  • 80 Plock JA, Schnider JT, Zhang W. , et al. Adipose- and bone marrow-derived mesenchymal stem cells prolong graft survival in vascularized composite allotransplantation. Transplantation 2015; 99 (09) 1765-1773
    CrossrefPubMedGoogle Scholar
  • 81 Aksu AE, Horibe E, Sacks J. , et al. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol 2008; 127 (03) 348-358
    CrossrefPubMedGoogle Scholar
  • 82 Kuo YR, Chen CC, Goto S. , et al. Immunomodulatory effects of bone marrow-derived mesenchymal stem cells in a swine hemi-facial allotransplantation model. PLoS One 2012; 7 (04) e35459
    CrossrefPubMedGoogle Scholar
  • 83 Zhou Y, Shan J, Li Y. , et al. Adoptive transfusion of tolerance dendritic cells prolongs the survival of skin allografts in mice: a systematic review. J Evid Based Med 2013; 6 (02) 90-103
    CrossrefPubMedGoogle Scholar
  • 84 Eggenhofer E, Benseler V, Kroemer A. , et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3: 297
    PubMedGoogle Scholar
  • 85 Rombouts WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003; 17 (01) 160-170
    CrossrefPubMedGoogle Scholar
  • 86 Wagner W, Horn P, Castoldi M. , et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 2008; 3 (05) e2213
    CrossrefPubMedGoogle Scholar
  • 87 Hematti P. Mesenchymal stromal cells and fibroblasts: a case of mistaken identity?. Cytotherapy 2012; 14 (05) 516-521
    CrossrefPubMedGoogle Scholar
  • 88 Vacanti V, Kong E, Suzuki G, Sato K, Canty JM, Lee T. Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol 2005; 205 (02) 194-201
    CrossrefPubMedGoogle Scholar
  • 89 Wagner W, Ho AD, Zenke M. Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev 2010; 16 (04) 445-453
    CrossrefPubMedGoogle Scholar
  • 90 Berger TG, Schulze-Koops H, Schäfer M, Müller E, Lutz MB. Immature and maturation-resistant human dendritic cells generated from bone marrow require two stimulations to induce T cell anergy in vitro. PLoS One 2009; 4 (08) e6645
    CrossrefPubMedGoogle Scholar
  • 91 Moreau A, Chiffoleau E, Beriou G. , et al. Superiority of bone marrow-derived dendritic cells over monocyte-derived ones for the expansion of regulatory T cells in the macaque. Transplantation 2008; 85 (09) 1351-1356
    CrossrefPubMedGoogle Scholar
  • 92 Ueno H, Schmitt N, Klechevsky E. , et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010; 234 (01) 199-212
    CrossrefPubMedGoogle Scholar
  • 93 Lutz MB, Suri RM, Niimi M. , et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000; 30 (07) 1813-1822
    CrossrefPubMedGoogle Scholar
  • 94 Chitta S, Santambrogio L, Stern LJ. GMCSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells. Immunol Lett 2008; 116 (01) 41-54
    CrossrefPubMedGoogle Scholar
  • 95 Gregori S, Tomasoni D, Pacciani V. , et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010; 116 (06) 935-944
    CrossrefPubMedGoogle Scholar
  • 96 Moreau A, Varey E, Bériou G. , et al. Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials. Front Immunol 2012; 3: 218
    PubMedGoogle Scholar
  • 97 Correale P, Campoccia G, Tsang KY. , et al. Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial. Eur J Cancer 2001; 37 (07) 892-902
    CrossrefPubMedGoogle Scholar
  • 98 Redman BG, Chang AE, Whitfield J. , et al. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 2008; 31 (06) 591-598
    CrossrefPubMedGoogle Scholar
  • 99 Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193 (02) 233-238
    CrossrefPubMedGoogle Scholar
  • 100 Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 2002; 100 (01) 174-177
    CrossrefPubMedGoogle Scholar
  • 101 Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34 (09) 2026-2032
    CrossrefPubMedGoogle Scholar
  • 102 Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol 2010; 29 (02) 156-183
    CrossrefPubMedGoogle Scholar
  • 103 Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010; 69 (11) 2042-2050
    CrossrefPubMedGoogle Scholar
  • 104 Raϊch-Regué D, Grau-López L, Naranjo-Gómez M. , et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012; 42 (03) 771-782
    CrossrefPubMedGoogle Scholar
  • 105 Barrett AJ, Rezvani K, Solomon S. , et al. New developments in allotransplant immunology. Hematology (Am Soc Hematol Educ Program) 2003; 20 03: 350-371
    PubMedGoogle Scholar
  • 106 Ravindra KV, Wu S, McKinney M, Xu H, Ildstad ST. Composite tissue allotransplantation: current challenges. Transplant Proc 2009; 41 (09) 3519-3528
    CrossrefPubMedGoogle Scholar